Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine in Infants and Toddlers When Administered Concomitantly With Routine Pediatric Vaccines in the United Kingdom
Condition: Meningococcal Infection Interventions: Biological: Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid conjugate vaccine MenACYW conjugate vaccine; Biological: Meningococcal group B vaccine; Biological: Diphtheria, tetanus, pertussis (acellular component), hepatitis B, poliomyelitis (inactivated) vaccine; Biological: Human rotavirus RIX4414 strain vaccine; Biological: Pneumococcal 13-valent polysaccharide conjugate vaccine Sponsor: Sanofi Pasteur, a Sanofi Company Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: ActHIB | Diphtheria | Hepatitis | Hepatitis B | Hepatitis Vaccine | Men | Meningitis | Meningitis Vaccine | Pediatrics | Pneomococcal Vaccine | Polio | Polio Vaccine | Rotavirus | Rotavirus Vaccine | Tetanus | Tetanus Diptheria Pertussis Vaccine Tdap,Dtap,Dpt | Tetanus Vaccine | UK Health | Vaccines | Whooping Cough (Pertussis) Vaccine